Adaptive Biotechnologies (NASDAQ:ADPT) CFO Sells $77,220.00 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CFO Kyle Piskel sold 4,290 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $18.00, for a total transaction of $77,220.00. Following the completion of the sale, the chief financial officer owned 216,637 shares of the company’s stock, valued at $3,899,466. The trade was a 1.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Kyle Piskel also recently made the following trade(s):

• On Friday, November 28th, Kyle Piskel sold 162,820 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $19.50, for a total transaction of $3,174,990.00.
• On Monday, November 17th, Kyle Piskel sold 238 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.05, for a total transaction of $3,343.90.

Adaptive Biotechnologies Price Performance

Shares of Adaptive Biotechnologies stock opened at $17.52 on Friday. The firm has a 50 day simple moving average of $16.60 and a 200 day simple moving average of $14.50. Adaptive Biotechnologies Corporation has a fifty-two week low of $6.26 and a fifty-two week high of $20.76. The firm has a market cap of $2.67 billion, a P/E ratio of -32.44 and a beta of 2.18.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. The firm had revenue of $93.97 million for the quarter, compared to analyst estimates of $58.76 million. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The business’s quarterly revenue was up 102.4% compared to the same quarter last year. During the same period last year, the company earned ($0.22) EPS. On average, sell-side analysts expect that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Analyst Upgrades and Downgrades

ADPT has been the subject of several recent research reports. Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 7th. Morgan Stanley began coverage on shares of Adaptive Biotechnologies in a research report on Monday, December 1st. They set an “equal weight” rating and a $21.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, October 8th. BTIG Research increased their price objective on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Finally, Piper Sandler raised their price objective on shares of Adaptive Biotechnologies from $15.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, October 15th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.11.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC raised its holdings in Adaptive Biotechnologies by 45.8% in the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock worth $2,265,000 after purchasing an additional 97,444 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Adaptive Biotechnologies by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock valued at $511,000 after buying an additional 2,914 shares during the period. Caxton Associates LLP bought a new stake in shares of Adaptive Biotechnologies in the 1st quarter valued at $93,000. Acadian Asset Management LLC raised its stake in Adaptive Biotechnologies by 44.1% during the 1st quarter. Acadian Asset Management LLC now owns 183,113 shares of the company’s stock worth $1,357,000 after buying an additional 56,058 shares during the period. Finally, Strs Ohio acquired a new stake in Adaptive Biotechnologies during the 1st quarter worth $611,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.